I don't doubt something like that could happen for BTI with just a small Phase I study.   Demonstrate safety and efficacy, especially for XB3-001, and BTI will zoom waaaaaaay up.

But I don't think the current pipeline timeline for Phase I XB3-001 starting Q1, 2022 will happen.  I suspect in the next presentation or two, we'll see the timeline for 001 get bumped out 6+ months. We don't even have a partner yet (who is supposed to fund it).  And, according to the pipeline, 001 is ahead of all other programs (including Chiesi).  I hope I'm wrong.  I have no doubt mgmt is doing their best to secure a partner and move 001 forward ASAP.  Hopefully we get a partner and a more certain 001 timeline soon.